ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...
A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...
This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...
Study Objective: Compare longitudinal HIV-1 antibody responses among HIV-1 infected participants that either did or did not...
